Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Millennium Pharmacon International Tbk's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was Rp7.93.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was Rp30.51.
During the past 12 months, PT Millennium Pharmacon International Tbk's average earnings per share (NRI) Growth Rate was 93.00% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 12.40% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 50.40% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 3.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
ISX:SDPC'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -47.6 Med: 9.5 Max: 110.4
Current: 12.4
During the past 13 years, PT Millennium Pharmacon International Tbk's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 110.40% per year. The lowest was -47.60% per year. And the median was 9.50% per year.
ISX:SDPC's 3-Year EPS without NRI Growth Rate is ranked better than 69.9% of 103
companies
in the Medical Distribution industry
Industry Median: 2.3
vs ISX:SDPC: 12.40
PT Millennium Pharmacon International Tbk (ISX:SDPC) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
PT Millennium Pharmacon International Tbk EPS without NRI Related Terms
PT Millennium Pharmacon International Tbk EPS without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Millennium Pharmacon International Tbk EPS without NRI Chart
PT Millennium Pharmacon International Tbk Annual Data
ISX:SDPC vs MCK, COR, CAH: EPS without NRI Comparison
For the Medical Distribution subindustry, PT Millennium Pharmacon International Tbk's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Millennium Pharmacon International Tbk PE Ratio without NRI vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Millennium Pharmacon International Tbk's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where PT Millennium Pharmacon International Tbk's PE Ratio without NRI falls into.
PT Millennium Pharmacon International Tbk EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp30.51
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Millennium Pharmacon International Tbk (ISX:SDPC) has a EPS without NRI of Rp30.51 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on PT Millennium Pharmacon International Tbk and its competitors. According to the industry distribution chart, PT Millennium Pharmacon International Tbk ranks #31 out of 103 companies in the Medical Distribution industry, placing it in the top 30.1%.
Is PT Millennium Pharmacon International Tbk's EPS without NRI too high?
PT Millennium Pharmacon International Tbk's current EPS without NRI is Rp30.51. Based on the distribution chart, PT Millennium Pharmacon International Tbk ranks #31 out of 103 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, PT Millennium Pharmacon International Tbk has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Millennium Pharmacon International Tbk's EPS without NRI compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Millennium Pharmacon International Tbk ranks #31 out of 103 companies for EPS without NRI. This puts PT Millennium Pharmacon International Tbk in the upper half of its industry. The industry median EPS without NRI is 2.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Distribution company?
The median EPS without NRI among Medical Distribution companies is 2.30, based on 103 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on PT Millennium Pharmacon International Tbk and its competitors. For the Medical Distribution industry, the median EPS without NRI is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Millennium Pharmacon International Tbk's current EPS without NRI is Rp30.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Millennium Pharmacon International Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk (ISX:SDPC) is currently considered Fairly Valued. The stock's GF Value™ is Rp166.83, compared to a current price of Rp181.00 — trading 8.5% above its estimated fair value. The current EPS without NRI is Rp30.51. PT Millennium Pharmacon International Tbk's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For PT Millennium Pharmacon International Tbk (ISX:SDPC), the current EPS without NRI is Rp30.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Millennium Pharmacon International Tbk (ISX:SDPC) Overvalued in 2026?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk stock appears to be overvalued.
The current stock price of Rp181.00 is trading 8.5% above its estimated GF Value™ of Rp166.83.
GuruFocus considers PT Millennium Pharmacon International Tbk to be Fairly Valued.
Key valuation signals for ISX:SDPC:
EPS without NRI: Rp30.51
GF Value™: Rp166.83 vs. price of Rp181.00 (8.5% above fair value)
No single metric tells the full story. See the ISX:SDPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressJl. Sultan Iskandar Muda No 18/Jl. Bungur No. 1, Crown Bungur Arteri Lantai 2-4, Kel. Kebayoran Lama Selatan, Kec. Kebayoran Lama, South Jakarta, Jakarta, IDN, 12240
PT Millennium Pharmacon International Tbk is engaged in distributing medicines, food supplements, and medical disposables. The group's operating segments are Prescription medicine, Non-prescription medicine, Medical Disposables, and others, of which the majority of revenue is derived from the Prescription Medicine segment. The company's geographical segments are Jawa, Sumatra, Kalimantan, Sulawesi, and Bali & Lombok.
79GF Score
Get the complete analysis for ISX:SDPC
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SDPC has been successfully added to your 
